Immunomodulatory therapy in dengue: need for clinical trials and evidence base

Arch Dis Child. 2023 Jun;108(6):451-452. doi: 10.1136/archdischild-2022-324100. Epub 2022 Jun 9.

Authors

C S Bhat¹, R Shetty², Balasubramanian Sundaram³, A V Ramanan⁴

Affiliations

¹ Paediatric Rheumatology Services, Rainbow Children's Hospital, Bangalore, India.
² Paediatric Intensive Care Services, Rainbow Children's Hospital, Bangalore, India.
³ Department of Pediatrics, Kanchi Kamakoti CHILDS Trust Hospital, Nungambakkam, India.
⁴ Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, UK a.ramanan@bristol.ac.uk.

PMID: 35680407
DOI: 10.1136/archdischild-2022-324100

No abstract available

Keywords: Child Health; Ethics; Global Health; Infectious Disease Medicine; Intensive Care Units, Paediatric.

MeSH terms

Child
Dengue* / therapy
Humans
Immunomodulation
Intensive Care Units, Pediatric*